Structure and inhibitor binding mechanisms of 11β-hydroxysteroid dehydrogenase type 1

Current Chemical Biology

Volumn 3, Issue 2, 2009, Pages 159-170

  Wang, Zhulun ^a   Wang, Minghan ^a  

^a AMGEN INC   (United States)

Author keywords

11 Hydroxysteroid dehydrogenase; Active site; CBX; Co crystal structure; Cortisol; Dimer partner; Inhibitor binding

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 1 INHIBITOR; ADMANTANE; ANTIDIABETIC AGENT; ARYLSULFONYLPIPERAZINE; CARBENOXOLONE; CORTICOSTERONE; ENZYME INHIBITOR; GLYCYRRHETINIC ACID; LYSINE; PYRIDINE AMIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SERINE; THIAZOLONE; TRIAZOLE DERIVATIVE; TYROSINE; UNCLASSIFIED DRUG;

CRYSTAL STRUCTURE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; HYDROGEN BOND; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; REVIEW; STRUCTURE ANALYSIS;

EID: 68449101064     PISSN: 18723136     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231309788166433     Document Type: Review

References (75)

1. Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003; 88: 5593-602.
2. Faggiano A, Pivonello R, Spiezia S, et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 2003; 88: 2527-33.
3. Findling JW, Raff H. Screening and diagnosis of Cushing's syndrome. Endocrinol Metab Clin North Am 2005; 34: 385-402, ix-x.
4. Jacobson PB, von Geldern TW, Ohman L, et al. Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes. J Pharmacol Exp Ther 2005; 314: 191-200.
5. Zinker B, Mika A, Nguyen P, et al. Liver-selective glucocorticoid receptor antagonism decreases glucose production and increases glucose disposal, ameliorating insulin resistance. Metabolism 2007; 56: 380-7.
6. Lamberts SW, Koper JW, de Jong FH. The endocrine effects of long-term treatment with mifepristone (RU 486). J Clin Endocrinol Metab 1991; 73: 187-91.
7. Pont A, Graybill JR, Craven PC, et al. High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med 1984; 144: 2150-3.
8. Bujalska I, Shimojo M, Howie A, Stewart PM. Human 11β-hydroxysteroid dehydrogenase: studies on the stably transfected isoforms and localization of the type 2 isozyme within renal tissue. Steroids 1997; 62: 77-82.
9. Jamieson PM, Chapman KE, Edwards CR, Seckl JR. 11β-hydroxysteroid dehydrogenase is an exclusive 11β-reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology 1995; 136: 4754-61.
10. Kannisto K, Pietilainen KH, Ehrenborg E, et al. Overexpression of 11β-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. J Clin Endocrinol Metab 2004; 89: 4414-21.
11. Rask E, Olsson T, Soderberg S, et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001; 86: 1418-21.
12. Rask E, Walker BR, Soderberg S, et al. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11??-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 2002; 87: 3330-6.
13. Wake DJ, Rask E, Livingstone DE, Soderberg S, Olsson T, Walker BR. Local and systemic impact of transcriptional up-regulation of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J Clin Endocrinol Metab 2003; 88: 3983-8.
14. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166-70.
15. Masuzaki H, Yamamoto H, Kenyon CJ, et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 2003; 112: 83-90.
16. Paterson JM, Morton NM, Fievet C, et al. Metabolic syndrome without obesity: Hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA 2004; 101: 7088-93.
17. Kotelevtsev Y, Holmes MC, Burchell A, et al. 11β-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 1997; 94: 14924-9.
18. Morton NM, Holmes MC, Fievet C, et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 2001; 276: 41293-300.
19. Morton NM, Paterson JM, Masuzaki H, et al. Novel adipose tissuemediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 2004; 53: 931-8.
20. Kershaw EE, Morton NM, Dhillon H, Ramage L, Seckl JR, Flier JS. Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes 2005; 54: 1023-31.
21. Ozols J. Lumenal orientation and post-translational modifications of the liver microsomal 11β-hydroxysteroid dehydrogenase. J Biol Chem 1995; 270: 2305-12.
22. Odermatt A, Arnold P, Stauffer A, Frey BM, Frey FJ. The Nterminal anchor sequences of 11β-hydroxysteroid dehydrogenases determine their orientation in the endoplasmic reticulum membrane. J Biol Chem 1999; 274: 28762-70.
23. Walker EA, Ahmed A, Lavery GG, et al. 11β-Hydroxysteroid dehydrogenase type 1 regulation by intracellular glucose 6-phosphate provides evidence for a novel link between glucose metabolism and hypothalamo-pituitary-adrenal axis function. J Biol Chem 2007; 282: 27030-6.
24. Maser E, Volker B, Friebertshauser J. 11β-Hydroxysteroid dehydrogenase type 1 from human liver: dimerization and enzyme cooperativity support its postulated role as glucocorticoid reductase. Biochemistry 2002; 41: 2459-65.
25. Walker EA, Clark AM, Hewison M, Ride JP, Stewart PM. Functional expression, characterization, and purification of the catalytic domain of human 11β-hydroxysteroid dehydrogenase type 1. J Biol Chem 2001; 276: 21343-50.
26. Oppermann UC, Netter KJ, Maser E. Cloning and primary structure of murine 11β-hydroxysteroid dehydrogenase/microsomal carbonyl reductase. Eur J Biochem 1995; 227: 202-8.
27. Tannin GM, Agarwal AK, Monder C, New MI, White PC. The human gene for 11β-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J Biol Chem 1991; 266: 16653-8.
28. Oppermann U, Filling C, Hult M, et al. Short-chain dehydrogenases/ reductases (SDR): the 2002 update. Chem Biol Interact 2003; 143-144: 247-53.
29. Obeyesekere VR, Trzeciak WH, Li KX, Krozowski ZS. Serines at the active site of 11β-hydroxysteroid dehydrogenase type I determine the rate of catalysis. Biochem Biophys Res Commun 1998; 250: 469-73.
30. Diederich S, Grossmann C, Hanke B, et al. In the search for specific inhibitors of human 11β-hydroxysteroid-dehydrogenases (11β-HSDs): chenodeoxycholic acid selectively inhibits 11β-HSD-I. Eur J Endocrinol 2000; 142: 200-7.
31. Hult M, Jornvall H, Oppermann UC. Selective inhibition of human type 1 11β-hydroxysteroid dehydrogenase by synthetic steroids and xenobiotics. FEBS Lett 1998; 441: 25-8.
32. Kim KW, Wang Z, Busby J, et al. The role of tyrosine 177 in human 11β-hydroxysteroid dehydrogenase type 1 in substrate and inhibitor binding: an unlikely hydrogen bond donor for the substrate. Biochim Biophys Acta 2006; 1764: 824-30.
33. Kim KW, Wang Z, Busby J, et al. The selectivity of tyrosine 280 of human 11beta-hydroxysteroid dehydrogenase type 1 in inhibitor binding. FEBS Lett 2007; 581: 995-9.
34. Hosfield DJ, Wu Y, Skene RJ, et al. Conformational flexibility in crystal structures of human 11β-hydroxysteroid dehydrogenase type I provide insights into glucocorticoid interconversion and enzyme regulation. J Biol Chem 2005; 280: 4639-48.
35. Agarwal AK, Mune T, Monder C, White PC. Mutations in putative glycosylation sites of rat 11β-hydroxysteroid dehydrogenase affect enzymatic activity. Biochim Biophys Acta 1995; 1248: 70-4.
36. Blum A, Martin HJ, Maser E. Human 11β-hydroxysteroid dehydrogenase type 1 is enzymatically active in its nonglycosylated form. Biochem Biophys Res Commun 2000; 276: 428-34.
37. Sahni-Arya B, Flynn MJ, Bergeron L, et al. Cofactor-specific modulation of 11β-hydroxysteroid dehydrogenase 1 inhibitor potency. Biochim Biophys Acta 2007; 1774: 1184-91.
38. Shafqat N, Elleby B, Svensson S, et al. Comparative enzymology of 11β-hydroxysteroid dehydrogenase type 1 from glucocorticoid resistant (Guinea pig) versus sensitive (Human) species. J Biol Chem 2003; 278: 2030-5.
39. Ogg D, Elleby B, Norstrom C, et al. The crystal structure of guinea pig 11β-hydroxysteroid dehydrogenase type 1 provides a model for enzyme-lipid bilayer interactions. J Biol Chem 2005; 280: 3789-94.
40. Zhang J, Osslund TD, Plant MH, et al. Crystal structure of murine 11β-hydroxysteroid dehydrogenase 1: an important therapeutic target for diabetes. Biochemistry 2005; 44: 6948-57.
41. Sorensen B, Winn M, Rohde J, et al. Adamantane sulfone and sulfonamide 11β-HSD1 Inhibitors. Bioorg Med Chem Lett 2007; 17: 527-32.
42. Sun D, Wang Z, Di Y, et al. Discovery and initial SAR of arysulfonylpiperazine inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). Bioorg Med Chem Lett 2008; 18: 3513-6.
43. Yuan C, St Jean DJ, Jr., Liu Q, et al. The discovery of 2-anilinothiazolones as 11β-HSD1 inhibitors. Bioorg Med Chem Lett 2007; 17: 6056-61.
44. Patel JR, Shuai Q, Dinges J, et al. Discovery of adamantane ethers as inhibitors of 11β-HSD-1: Synthesis and biological evaluation. Bioorg Med Chem Lett 2007; 17: 750-5.
45. Hale C, Veniant M, Wang Z, et al. Structural characterization and pharmacodynamic effects of an orally active 11β-hydroxysteroid dehydrogenase type 1 inhibitor. Chem Biol Drug Des 2008; 71: 36-44.
46. Johansson L, Fotsch C, Bartberger MD, et al. 2-Amino-1,3-thiazol-4(5H)-ones as potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice. J Med Chem 2008; 51: 2933-43.
47. Wang H, Ruan Z, Li JJ, et al. Pyridine amides as potent and selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Bioorg Med Chem Lett 2008; 18: 3168-72.
48. Julian JD, Bostick T, Caille S, et al. Discovery and biological evaluation of novel benzamide derivatives as potent 11β-HSD1 inhibitors for the treatment of type 2 diabetes. 234th ACS National Meeting. Boston, USA (2007).
49. Sawicki MW, Erman M, Puranen T, Vihko P, Ghosh D. Structure of the ternary complex of human 17β-hydroxysteroid dehydrogenase type 1 with 3-hydroxyestra-1,3,5,7-tetraen-17-one (equilin) and NADP+. Proc Natl Acad Sci USA 1999; 96: 840-5.
50. Tanaka N, Nonaka T, Nakanishi M, Deyashiki Y, Hara A, Mitsui Y. Crystal structure of the ternary complex of mouse lung carbonyl reductase at 1.8 Å resolution: the structural origin of coenzyme specificity in the short-chain dehydrogenase/reductase family. Structure 1996; 4: 33-45.
51. + in 17β-hydroxysteroid dehydrogenase. J Biol Chem 1998; 273: 8145-52.
52. Jornvall H, Persson B, Krook M, et al. Short-chain dehydrogenases/ reductases (SDR). Biochemistry 1995; 34: 6003-13.
53. + identifies two principal targets for the design of inhibitors. Structure 1996; 4: 905-15.
54. Ghosh D, Pletnev VZ, Zhu DW, et al. Structure of human estrogenic 17β-hydroxysteroid dehydrogenase at 2.20 Å resolution. Structure 1995; 3: 503-13.
55. Tanaka N, Nonaka T, Tanabe T, Yoshimoto T, Tsuru D, Mitsui Y. Crystal structures of the binary and ternary complexes of 7α-hydroxysteroid dehydrogenase from Escherichia coli. Biochemistry 1996; 35: 7715-30.
56. Sandeep TC, Yau JL, MacLullich AM, et al. 11β-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc Natl Acad Sci USA 2004; 101: 6734-9.
57. Flyren K, Bergquist LO, Castro VM, et al. Piperidine amides as 11β-hydroxysteroid dehydrogenase type 1 inhibitors. Bioorg Med Chem Lett 2007; 17: 3421-5.
58. Sorensen B, Rohde J, Wang J, et al. Adamantane 11β-HSD-1 inhibitors: application of an isocyanide multicomponent reaction. Bioorg Med Chem Lett 2006; 16: 5958-62.
59. St. Jean DJ, Jr., Yuan C, Bercot EA, et al. 2-(S)-phenethylaminothiazolones as potent, orally efficacious inhibitors of 11β-hydroxysteriod dehydrogenase type 1. J Med Chem 2007; 50: 429-32.
60. Olson S, Aster SD, Brown K, et al. Adamantyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Bioorg Med Chem Lett 2005; 15: 4359-62.
61. Hult M, Shafqat N, Elleby B, et al. Active site variability of type 1 11β-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons. Mol Cell Endocrinol 2006; 248: 26-33.
62. Sutin L, Andersson S, Bergquist L, et al. Oxazolones as potent inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Bioorg Med Chem Lett 2007; 17: 4837-40.
63. Rohde J, Pliushchev M, Sorensen B, et al. Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11β-hydroxysteroid dehydrogenase type 1 inhibitors. J Med Chem. 2007; 50: 149-64.
64. Richards S, Sorensen B, Jae HS, et al. Discovery of potent and selective inhibitors of 11β-HSD1 for the treatment of metabolic syndrome. Bioorg Med Chem Lett 2006; 16: 6241-5.
65. Barf T, Vallgarda J, Emond R, et al. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11β-hydroxysteroid dehydrogenase type 1. J Med Chem 2002; 45: 3813-5.
66. Xiang J, Ipek M, Suri V, et al. Synthesis and biological evaluation of sulfonamidooxazoles and β-keto sulfones: selective inhibitors of 11β-hydroxysteroid dehydrogenase type I. Bioorg Med Chem Lett 2005; 15: 2865-9.
67. Webster SP, Ward P, Binnie M, et al. Discovery and biological evaluation of adamantyl amide 11β-HSD1 inhibitors. Bioorg Med Chem Lett 2007; 17: 2838-43.
68. Coppola GM, Kukkola PJ, Stanton JL, et al. Perhydroquinolylbenzamides as novel inhibitors of 11β-hydroxysteroid dehydrogenase type 1. J Med Chem 2005; 48: 6696-712.
69. Su X, Vicker N, Ganeshapillai D, et al. Benzothiazole derivatives as novel inhibitors of human 11β-hydroxysteroid dehydrogenase type 1. Mol Cell Endocrinol 2006; 248: 214-7.
70. Julian LD, Wang Z, Bostick T, et al. Discovery of novel, potent benzamide inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) exhibiting oral activity in an enzyme inhibition ex vivo model. J Med Chem 2008; 51: 3953-60.
71. Tu H, Powers JP, Liu J, et al. Distinctive molecular inhibition mechanisms for selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1. Bioorg Med Chem 2008; 16: 8922-31.
72. Gu X, Dragovic J, Koo GC, et al. Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors of 11β-HSD1: novel therapeutic agents for the treatment of metabolic syndrome. Bioorg Med Chem Lett 2005; 15: 5266-9.
73. Aster SD, Graham DW, Kharbanda D, et al. Bis-aryl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Bioorg Med Chem Lett 2008; 18: 2799-804.
74. Zhu Y, Olson SH, Graham D, et al. Phenylcyclobutyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type I. Bioorg Med Chem Lett 2008; 18: 3412-6.
75. Zhu Y, Olson SH, Hermanowski-Vosatka A, et al. 4-Methyl-5-phenyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type I. Bioorg Med Chem Lett 2008; 18: 3405-11.